Key result
Nisoldipine CC matches felodipine in antihypertensive response rates.
Why the study?
The comparative efficacy and safety of nisoldipine coat-core and felodipine in patients with mild-to-moderate hypertension required evaluation.
RCT (n=229)
Double-blind
randomised
Yes
Answers are grounded in this paper and cite their sources.
Supports nisoldipine CC as an alternative to felodipine; confirms comparable efficacy in this RCT.
The efficacy and safety of nisoldipine CC and felodipine were compared in a multicentre, randomised, double-blind, trial in patients with mild-to-moderate hypertension (n = 229). Following a two-week placebo run-in period, patients were randomised to 16 weeks' active treatment with nisoldipine coat core (CC) 20-40 mg or felodipine 5-10 mg once daily. At week 16, a higher proportion of patients in the nisoldipine CC group were on low-dose therapy (51% vs 36%, p = 0.07). The proportion of treatment responders was 77.8% with nisoldipine CC and 66.5% with felodipine. The mean change from baseline in systolic/diastolic blood pressure was -18.8/-13.6 mmHg with nisoldipine CC and -17.4/-11.3 mmHg with felodipine. The most common adverse events included peripheral oedema and headache; neither treatment affected heart rate. Thus, nisoldipine CC and felodipine provide comparable antihypertensive efficacy. The adverse effects of both drugs are related to their vasodilator properties and are common to the class.
No takes yet. Share an insight, caveat, or question.
Höglund et al. (1998) conducted an RCT in mild-to-moderate hypertension (n=229). Nisoldipine coat core (CC) vs. Felodipine 5-10 mg once daily was evaluated on Proportion of treatment responders. Nisoldipine CC provided comparable antihypertensive efficacy to felodipine, with treatment response rates of.
Synapse has enriched 10 related papers. Consider them for comparative context: